Nicholas Lydon

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nicholas Lydon
Nicholas Lydon.jpg
Born (1957-02-27) February 27, 1957 (age 57)[citation needed]
Institutions
Alma mater
Thesis Studies on the hormone-sensitive adenylate cyclase from bovine corpus luteum (1982)
Known for
  • Gleevec
  • AnaptysBio
  • BluePrint Medicines
Notable awards
Website
royalsociety.org/people/nicholas-lydon

Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur.[1] In 2009 he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukemia (CML), which converted a fatal cancer into a manageable chronic condition.[2][3][4][5] [6][7]

Education[edit]

Lydon was educated at Strathallan School near Perth, Scotland.[8] He earned a Bachelor of Science degree in biochemistry from the University of Leeds, England in 1978 and received his Ph.D in biochemistry from the University of Dundee, Scotland in 1982.[9][8]

Career[edit]

In 1982 Lydon accepted a position with Schering-Plough based in France as Charge de Recherche.[3] Three years later he moved to Switzerland to work with Ciba-Geigy Pharmaceuticals, with whom he developed Gleevec.[8] In 1997 he established Kinetex Pharmaceuticals in Boston which was acquired by Amgen in 2000, with whom he worked until 2002.[8] Thereafter, he established several companies that continue to develop drugs to treat various conditions.[8]

Honours and awards[edit]

Lydon's nomination for the Royal Society reads:

References[edit]

  1. ^ "Nicholas Lydon". ScienceHeroes.com. 2010. Retrieved 13 February 2013. 
  2. ^ "Lasker - DeBakey Clinical Medical Research Award: Award Description". Lasker Foundation. Retrieved 16 August 2010. 
  3. ^ a b c d e f g h "Laureates of the Japan Prize". The Japan Prize Foundation. 2012. Retrieved 13 February 2013. 
  4. ^ Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. (2001). "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia". New England Journal of Medicine 344 (14): 1031–1037. doi:10.1056/NEJM200104053441401. PMID 11287972. 
  5. ^ List of publications from Microsoft Academic Search
  6. ^ Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. (1996). "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells". Nature medicine 2 (5): 561–566. doi:10.1038/nm0596-561. PMID 8616716. 
  7. ^ Buchdunger, E.; Cioffi, C. L.; Law, N.; Stover, D.; Ohno-Jones, S.; Druker, B. J.; Lydon, N. B. (2000). "Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors". The Journal of pharmacology and experimental therapeutics 295 (1): 139–145. PMID 10991971. 
  8. ^ a b c d e "Dr Nicholas Lydon". University of Dundee. 2011. Retrieved 13 February 2013. 
  9. ^ Lydon, Nicholas B. (1982). Studies on the hormone-sensitive adenylate cyclase from bovine corpus luteum (PhD thesis). University of Dundee. (subscription required)
  10. ^ a b "Dr Nicholas Lydon". Royal Society. 2013. Retrieved 29 May 2013. 
  11. ^ "GlaxoSmithKline prize". Royal Society. Retrieved 12 September 2013.